<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Vinogradov AA</submitter><funding>Japan Agency for Medical Research and Development</funding><funding>Japan Society for the Promotion of Science</funding><pagination>20332-20341</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9650704</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>144(44)</volume><pubmed_abstract>Bioengineering of ribosomally synthesized and post-translationally modified peptides (RiPPs) is an emerging approach to explore the diversity of pseudo-natural product structures for drug discovery purposes. However, despite the initial advances in this area, bioactivity reprogramming of multienzyme RiPP biosynthetic pathways remains a major challenge. Here, we report a platform for de novo discovery of functional thiopeptides based on reengineered biosynthesis of lactazole A, a RiPP natural product assembled by five biosynthetic enzymes. The platform combines in vitro biosynthesis of lactazole-like thiopeptides and mRNA display to prepare and screen large (≥10&lt;sup>12&lt;/sup>) combinatorial libraries of pseudo-natural products. We demonstrate the utility of the developed protocols in an affi</pubmed_abstract><journal>Journal of the American Chemical Society</journal><pubmed_title>De Novo Discovery of Thiopeptide Pseudo-natural Products Acting as Potent and Selective TNIK Kinase Inhibitors.</pubmed_title><pmcid>PMC9650704</pmcid><funding_grant_id>JP21H04712</funding_grant_id><funding_grant_id>JP16H06444</funding_grant_id><funding_grant_id>JP19K22243</funding_grant_id><funding_grant_id>JP20H05618</funding_grant_id><funding_grant_id>JP20K15407</funding_grant_id><funding_grant_id>JP19am0101070</funding_grant_id><funding_grant_id>JP20H02866</funding_grant_id><pubmed_authors>Hamada K</pubmed_authors><pubmed_authors>Nishimura H</pubmed_authors><pubmed_authors>Terasaka N</pubmed_authors><pubmed_authors>Zhang Y</pubmed_authors><pubmed_authors>Goto Y</pubmed_authors><pubmed_authors>Sengoku T</pubmed_authors><pubmed_authors>Suga H</pubmed_authors><pubmed_authors>Vinogradov AA</pubmed_authors><pubmed_authors>Onaka H</pubmed_authors><pubmed_authors>Okada C</pubmed_authors><pubmed_authors>Ogata K</pubmed_authors><pubmed_authors>Chang JS</pubmed_authors></additional><is_claimable>false</is_claimable><name>De Novo Discovery of Thiopeptide Pseudo-natural Products Acting as Potent and Selective TNIK Kinase Inhibitors.</name><description>Bioengineering of ribosomally synthesized and post-translationally modified peptides (RiPPs) is an emerging approach to explore the diversity of pseudo-natural product structures for drug discovery purposes. However, despite the initial advances in this area, bioactivity reprogramming of multienzyme RiPP biosynthetic pathways remains a major challenge. Here, we report a platform for de novo discovery of functional thiopeptides based on reengineered biosynthesis of lactazole A, a RiPP natural product assembled by five biosynthetic enzymes. The platform combines in vitro biosynthesis of lactazole-like thiopeptides and mRNA display to prepare and screen large (≥10&lt;sup>12&lt;/sup>) combinatorial libraries of pseudo-natural products. We demonstrate the utility of the developed protocols in an affi</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Nov</publication><modification>2026-05-31T23:07:47.76Z</modification><creation>2025-04-04T21:00:48.047Z</creation></dates><accession>S-EPMC9650704</accession><cross_references><pubmed>36282922</pubmed><doi>10.1021/jacs.2c07937</doi></cross_references></HashMap>